Research

Hormonal

GLP-1RA therapy was associated with a lower risk of all-cause mortality in nondiabetic patients with PAD (HR: 0.40; 95% CI: 0.35–0.46; p < 0.001).

GLP-1RAs may help reduce overall mortality in patients with PAD who do not have diabetes.

StrongSupportsmedium confidence
GLP-1RA use was associated with lower risk of all-cause mortality (HR: 0.40; 95% CI: 0.35–0.46; p < 0.001).
Emmanuel Daniel et al. · Journal of Investigative Medicine · 2025

Why this rating

Based on a large retrospective cohort study design.

Source

Impact of GLP-1 receptor agonists on cardiovascular outcomes in patients with peripheral artery disease without diabetes: A propensity score-matched analysis

Emmanuel Daniel et al. · Journal of Investigative Medicine · 2025

DOI 10.1177/10815589251393978

cohort · n=27110Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →